R&D in drug design
and profiling

Grounded in the fields of pharmacology and chemistry, Molecular Research Pharma CT is a contract research organization that stems from decades of R&D in drug design and profiling.

It is specialized in molecular modeling and bioinformatics.


Molecular Research Pharma CT is a CRO (Contract Research Organization) company for the research and development of new molecules derived from research in the areas of nutraceuticals, food, and dietary supplements, pharmaceuticals and para-pharmaceuticals.

The CRO offers, therefore, a service for present and future projects relatively:
-Development of new molecules;
-Repurposing and repositioning of existing molecules;
-Summary of nutraceuticals and/or food supplements.

Moreover, it boasts a vast network of collaborations including an international partnership for the development of new ligands to be applied in the field of diabetes.

TARGET MARKET: The company, through its technologies targets the following markets:

  • The drug-repositioning market: this market shows a TAM of 24.4b USD and projects a CAGR of 5.1% on average until 2023The CR


Molecular Research Pharma CT carries out the activities of a pharmaceutical research laboratory, with an application in the field of bioscience, biotechnology, and pharmacology, acting as a support to all companies in the portfolio of Cube Labs.

The spin-off offers support services in the development of molecules in the preclinical phase to pharmaceutical and biotech companies. Specifically, starting from the discovery and selection of new molecules, MRC deals with the non-clinical studies of pharmacology and toxicology, as well as the production of product quality data.

The procedures implemented are in accordance with GLP (Good Laboratory Practices).
The goal is to simplify the process of developing and marketing new drugs, so those new safe products can reach patients faster.

To accomplish this mission, Molecular Research Pharma CT relies on the expertise of its team and highly innovative equipment. The MRC project was born with the aim of carrying out research and development of new molecules in the therapeutic field, with particular attention to drugs active against rare diseases

Molecular Research and the development of new drugs

The company has been active for decades in the field of pharmacological research and development. In collaboration with an international academic partner he has developed a new drug to be applied for the treatment of type 2 diabetes mellitus.


Chiudi il menu